☆ 4.2 Article

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study

Martijn W. C. Verbeek et al.

Summary: The standardized EuroFlow protocol with CD19 as the primary B-cell marker allows for sensitive and reliable MRD assessment in BCP-ALL patients undergoing chemotherapy. An alternative gating strategy has been developed for analyzing MRD in patients treated with CD19-targeting therapies, showing high concordance with original MRD data despite variations. This indicates that overall MRD analysis remains accurate even with differences in CD19 expression.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Biology

Automated identification of cell populations in flow cytometry data with transformers

Matthias Woedlinger et al.

Summary: This study presents an automated method to compute the Minimal Residual Disease (MRD) value directly from FCM data in Acute Lymphoblastic Leukemia (ALL) patients. The method utilizes a neural network based on the transformer architecture to identify blast cells in samples. Evaluation on multiple datasets shows that the proposed method outperforms existing methods.

COMPUTERS IN BIOLOGY AND MEDICINE (2022)

Add to Collection

Article Hematology

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Clara Bueno et al.

Summary: CD19-directed immunotherapies have greatly improved the treatment of B-cell acute lymphoblastic leukemia (B-ALL). However, many patients still experience relapse. This study reveals the presence of pre-leukemic CD34(+)CD19(-)CD22(+) cells, which may contribute to phenotypic escape after CD19-directed immunotherapies.

BLOOD (2022)

Add to Collection

Article Medical Laboratory Technology

Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis

Kevin E. Shopsowitz et al.

Summary: In this study, optimized radar plots were developed for B-ALL MRD analysis, which successfully distinguished diverse B-lymphoblast populations and non-malignant CD19-positive populations. The optimized radar plots outperformed PCA plots and showed comparable performance to UMAP, with better generalizability to new data. This novel optimization strategy for radar plots could be applied to other MRD panels and clinical scenarios.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2022)

Add to Collection

Article Medical Laboratory Technology

B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting

Ekaterina Mikhailova et al.

Summary: The addition of CD22, CD24, and iCD79a with CD10 allows for the identification of B-lineage compartment including residual tumor blasts in virtually all patients with BCP-ALL after CD19-directed treatment for MFC-MRD searching.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2022)

Add to Collection

Review Oncology

Mesenchymal Stromal Cells (MSCs): An Ally of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells in Disease Maintenance and Progression within the Bone Marrow Hematopoietic Niche

Alessandra Fallati et al.

Summary: B-ALL is a common pediatric cancer with a low prognosis for relapsed/refractory patients. Recent studies have shown that the bone marrow microenvironment, particularly mesenchymal stromal cells (MSCs), play a crucial role in the progression of the disease and its resistance to therapy. Understanding the mechanisms by which MSCs nurture and protect B-ALL cells can lead to new therapeutic targets and improve patient outcomes.

CANCERS (2022)

Add to Collection

Article Oncology

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

Elen Oliveira et al.

Summary: An imbalanced ratio of endothelial cells (EC) to mesenchymal stem cells (MSC) in the bone marrow at day +78 of therapy is associated with a shorter disease-free survival (DFS) in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients, independent of their measurable residual disease (MRD) status.

CANCERS (2022)

Add to Collection

Article Pathology

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

Ludovic Lhermitte et al.

Summary: The study developed an automated gating and identification tool to categorize cell subsets within acute leukemia samples, using a reference database of normal samples to differentiate normal cells. The tool showed high correlation and concordance in classifying leukemic cells compared to manual analysis, demonstrating its potential to improve immunophenotyping quality in laboratories.

MODERN PATHOLOGY (2021)

Add to Collection

Article Hematology

Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease

Ekaterina Mikhailova et al.

Summary: CD19-directed treatment in BCP-ALL can lead to the presence of CD19-negative normal BCP, which may interfere with MFC-MRD monitoring and be mistaken for residual leukemic blasts.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report

Margarita Maurer-Granofszky et al.

Summary: Standardization of flow cytometric assessment of minimal residual disease in acute lymphoid leukemia is essential for international collaborative trials. A comprehensive training and quality control program is needed to achieve concordant results across multiple laboratories. Continuous education and quality control measures significantly improve inter-laboratory concordance rates and risk estimates in independent patient cohorts.

CANCERS (2021)

Add to Collection

Review Oncology

Current Status of CAR T Cell Therapy for Leukemias

Katherine Harris et al.

Summary: CAR T-cell therapy has become the standard of care for B-ALL patients and provides significant hope for relapsed and refractory diseases. Despite serious toxicities, the benefits outweigh the risks, especially as experience grows and toxicities are mitigated. CAR T cells can achieve complete remission and potentially lead to curative transplants.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

Add to Collection

Letter Oncology

Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy

Diane Libert et al.

LEUKEMIA (2020)

Add to Collection

Article Immunology

Improved Standardization of Flow Cytometry Diagnostic Screening of Primary Immunodeficiency by Software-Based Automated Gating

Eleni Linskens et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Biochemical Research Methods

Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning

Michael Reiter et al.

CYTOMETRY PART A (2019)

Add to Collection

Review Biochemical Research Methods

From big flow cytometry datasets to smart diagnostic strategies: The EuroFlow approach

C. E. Pedreira et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2019)

Add to Collection

Article Biochemical Research Methods

EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets

Juan Flores-Montero et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2019)

Add to Collection

Review Biochemical Research Methods

Immunophenotypic dissection of normal hematopoiesis

Alberto Orfao et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2019)

Add to Collection

Article Medical Laboratory Technology

A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy

Sindhu Cherian et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)

Add to Collection

Article Medical Laboratory Technology

Accurate quantification of fourteen normal bone marrow cell subsets in infants to the elderly by flow cytometry

Julie Pont et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)

Add to Collection

Article Hematology

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Prisca Theunissen et al.

BLOOD (2017)

Add to Collection

Article Oncology

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

J. Flores-Montero et al.

LEUKEMIA (2017)

Add to Collection

Review Hematology

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Jacques J. M. van Dongen et al.

BLOOD (2015)

Add to Collection

Article Medical Laboratory Technology

Detection of minimal residual disease in B lymphoblastic leukemia using viSNE

Joseph A. DiGiuseppe et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)

Add to Collection

Review Medical Laboratory Technology

Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia

Giuseppe Gaipa et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)

Add to Collection

Review Biotechnology & Applied Microbiology

Overview of clinical flow cytometry data analysis: recent advances and future challenges

Carlos E. Pedreira et al.

TRENDS IN BIOTECHNOLOGY (2013)

Add to Collection

Article Biochemical Research Methods

Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data

Karel Fiser et al.

CYTOMETRY PART A (2012)

Add to Collection

Article Oncology

Redirecting specificity of T-cell Populations for CD19 using the Sleeping beauty system

Harjeet Singh et al.

CANCER RESEARCH (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.